Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires

Journal of Virology

Volumn 71, Issue 10, 1997, Pages 7461-7469

  Dimasi, Nazzareno ^a   Martin, Franck ^a   Volpari, Cinzia ^a   Brunetti, Mirko ^a   Biasiol, Gabriella ^a   Altamura, Sergio ^a   Cortese, Riccardo ^a   De Francesco, Raffaele ^a   Steinkühler, Christian ^a   Sollazzo, Maurizio ^a  

^a IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; TRYPSIN INHIBITOR; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; ENZYME INHIBITION; HEPATITIS C VIRUS; NONHUMAN; PANCREAS SECRETION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; VIRUS REPLICATION;

EID: 0030796292     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.10.7461-7469.1997     Document Type: Article

References (47)

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1994. Current protocols in molecular biology, vol. 1 and II. Greene Publishing Associates, New York, N.Y.
2. Bartenschlager, R., L. Ahlborn-Laake, J. Mous, and H. Jacobsen. 1993. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67:3835-3844.
3. Bianchi, E., S. Venturing A. Pessi, A. Tramontane, and M. Sollazzo. 1994. High level expression and rational mutagenesis of a designed protein, the minibody: from an insoluble to a soluble molecule. J. Mol. Biol. 236:649-659.
4. Bode, W., and R. Huber. 1992. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204:433-451.
5. Braisted, A. C., and J. A. Wells. 1996. Minimizing a binding domain from protein A. Proc. Natl. Acad. Sci. USA 93:5688-5692.
6. Chambers, T. J., R. C. Weir, A. Grakoui, D. W. McCourt, F. F. Bazan, R. J. Fletterick, and C. M. Rice. 1990. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Natl. Acad. Sci. USA 87:8898-8902.
7. Chien, D., Q. L. Choo, A. Tabrizi, C. Kuo, J. McFarland, K. Berger, C. Lee, J. Shuster, T. Nguyen, D. Moyer, M. M. Tong, S. Furuta, M. Omata, G. Tegtmeyer, H. Alter, E. Schiff, L. Jeffers, M. Houghton, and G. Kuo. 1992. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc. Natl. Acad. Sci. USA 89:10011-10015.
8. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
9. Choo, Q. L., K. H. Richman, J. H. Ham, K. Berger, C. Lee, C. Dong, C. Gallegos, D. Coit, A. Medina-Selby, P. J. Barr, A. J. Weiner, D. W. Bradley, G. Kuo, and M. Houghton. 1991. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 88:2451-2455.
10. Dennis, M. S., and R. A. Lazarus. 1994. Kunitz domain inhibitor of tissue-factor VIIa. J. Biol. Chem. 269:22137-22144.
11. Eckart, M. R., M. Selby, F. Masiarz, C. Lee, K. Berger, K. Crawford, C. Kuo, G. Kuo, M. Houghton, and Q. L. Choo. 1993. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem. Biophys. Res. Commun. 192:399-406.
12. Failia, C., L. Tomei, and R. De Francesco. 1995. An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J. Virol. 69:1769-1777.
13. Failla, C., E. Pizzi, R. De Francesco, and A. Tramontano. 1996. Redesigning the substrate specificity of the hepatitis C virus NS3 protease. Folding Design 1:35-42.
14. Felici, F., L. Castagnoli, A. Musacchio, R. Jappelli, and G. Cesareni. 1991. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J. Mol. Biol. 222:301-310.
15. Grakoui, A., C. Wychowski, C. Lin, S. M. Feinstone, and C. M. Rice. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67:1385-1395.
16. Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 67:2832-2843.
17. Hijikata, M., N. Kato, Y. Ootusyama, M. Nakagawa, and K. Shimotohno. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. USA 88:5547-5551.
18. Hochuli, E., D. Gillessen, and H. P. Kocher. 1987. Specificity of the immunoadsorbent used for large-scale recovery of interferon alpha-2a. J. Chromatogr. 411:371-378.
19. Jappelli, R., A. Luzzago, P. Tataseo, I. Pernice, and G. Cesareni. 1992. Loop mutations can cause a substantial conformational change in the carboxy terminus of the ferritin protein. J. Mol. Biol. 227:532-543.
20. Kato, M., M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, T. Sugimura, and K. Shimotohno. 1990. Molecular cloning of human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. USA 87:9524-9528.
21. Kim, D. W., Y. Gwack, J. H. Han, and J. Choe. 1995. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem. Biophys. Res. Commun. 215:160-166.
22. Kim, J. L., K. A. Morgenstern, C. Lin, T. Fox, M. D. Dwyer, J. A. Landro, S. P. Chambers, W. Markland, C. A. Lepre, E. T. O'Malley, S. L. Harbeson, C. M. Rice, M. A. Murcko, P. R. Caron, and J. A. Thomson. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355.
23. Kuo, G., Q. L. Choo, H. J. Alter, G. L. Gitnick, A. G. Redecker, R. H. Purcell, T. Myamura, J. L. Dienstag, M. J. Alter, C. E. Syevens, G. E. Tagtmeyer, F. Bonino, M. Colombo, W. S. Lee, C. Kuo, K. Berger, J. R. Shister, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364.
24. Laskowski, M., Jr., and I. Kato. 1980. Protein inhibitors of proteinases. Annu. Rev. Biochem. 49:593-626.
25. Love, R. A., H. E. Parge, J. A. Wickersham, Z. Hostomsky, N. Habuka, E. W. Moomaw, T. Adachi, and Z. Hostomska. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-342.
26. Markland, W., A. C. Ley, S. W. Lee, and R. C. Ladner. 1996. Iterative optimization of high-affinity protease inhibitors using phage display. 1. Plasmin. Biochemistry 35:8045-8057.
27. Markland, W., A. C. Ley, and R. C. Ladner. 1996. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 35:8058-8067.
28. Martin, F., C. Toniatti, A. L. Salvati, S. Venturini, G. Ciliberto, R. Cortese, and M. Sollazzo. 1994. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. EMBO J. 13:5303-5309.
29. Martin, F., C. Toniatti, A. L. Salvati, G. Ciliberto, R. Cortese, and M. Sollazzo. 1996. Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed β-protein IL-6 antagonist. J. Mol. Biol. 255:86-97.
30. H domain antibody inhibitor of Hepatitis C Virus NS3 protease. Prot. Eng. 10:607-614.
31. McConnell, S. J., and R. H., Hoess. 1995. Tendamistat as a scaffold for conformationally constrained phage peptide libraries. J. Mol. Biol. 250:460-470.
32. Pessi, A., E. Bianchi, A. Crameri, S. Venturini, A. Tramontane, and M. Sollazzo. 1993. A designed metal-binding protein with a novel fold. Nature (London) 362:367-369.
33. Pizzi, E., A. Tramontano, L. Tomei, N. La Monica, C. Failla, M. Sardana, T. Wood, and R. De Francesco. 1994. Molecular model of the specificity pocket of the hepatitis C virus protease: implication for substrate recognition. Proc. Natl. Acad. Sci. USA 91:888-892.
34. Roberts, B. L., W. Markland, A. C. Ley, R. B. Kent, D. W. White, S. K. Guterman, and R. C. Ladner. 1992. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc. Natl. Acad. Sci. USA 89:2429-2433.
35. Röttgen, P., and J. Collins. 1995. A human pancreatic secretory trypsin inhibitor presenting a hypervariable highly constrained epitope via monovalent phagemid display. Gene 164:243-250.
36. Smith, G. P. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317.
37. Sollazzo, M., E. Bianchi, F. Felici, R. Cortese, and A. Pessi. 1995. Conformationally defined peptide libraries on phage: selectable templates for the design of pharmacological agents, p. 127-143. In R. Cortese (ed.), Combinatorial libraries, de Gruyter, Berlin, Germany.
38. Steinkühler, C., L. Tomei, and R. De Francesco. 1996. In vitro activity of hepatitis C virus protease NS3 purified from recombinant baculovirus-infected Sf9 cells. J. Biol. Chem. 271:6367-6373.
39. Steinkühler, C., A. Urbani, L. Tomei, G. Biasiol, M. Sardana, E. Bianchi, A. Pessi, and R. De Francesco. 1996. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J. Virol. 70:6694-6700.
40. Szardening, M., and J. Collins. 1990. A phasmid optimised for protein design projects: pMAFMPF. Gene 94:1-7.
41. Takamizawa, A., C. Mori, I. Fuke, S. Manabe, S. Murakami, J. Fujita, J. E. Onoshi, T. Andoh, I. Yoshida, and H. Okayama. 1991. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65:1105-1113.
42. Tomei, L., C. Failla, E. Santolini, R. De Francesco, and N. La Monica. 1993. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67:4017-4026.
43. Tomei, L., C. Failla, R. L. Vitale, E. Bianchi, and R. De Francesco. 1996. A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease. J. Gen. Virol. 77:1065-1070.
44. Urbani, A., E. Bianchi, F. Narjes, A. Tramontano, R. De Francesco, C. Steinkühler, and A. Pessi. 1997. Substrate specificity of the Hepatitis C Virus serine protease NS3. J. Biol. Chem. 272:9204-9209.
45. Wang, C. I., Q. Yang, and C. S. Craik. 1995. Isolation of a high affinity inhibitor of urokinase-type plasminogen activator by phage display of ecotin. J. Biol. Chem. 270:12250-12256.
46. Weiland, O. 1994. Interferon therapy in chronic hepatitis C virus infection. FEMS Microbiol. Rev. 14:279-288.
47. Zhao, B., L. R. Helms, R. L. Desjarlais, S. S. Abdel-Meguid, and R. Wetzel. 1995. A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold. Nat. Struct. Biol. 2:1131-1137.